12:00 AM
Nov 01, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

HspE7 (SGN-00101): Began Phase II testing

StressGen Biotechnologies Corp. (TSE:SSB), Victoria, B.C.
Product: HspE7 ( SGN-00101)
Business: Cancer
Therapeutic category:...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >